bevacizumab + capecitabine + cyclophosphamide

This is a combination therapy that includes bevacizumab (a monoclonal anti-vascular endothelial growth factor antibody), capecitabine (an oral fluoropyrimidine), and cyclophosphamide (an alkylating agent). The regimen is typically administered as metronomic chemotherapy, which involves continuous administration of low-dose chemotherapy. In clinical studies, patients received metronomic oral capecitabine (500 mg three times daily) and cyclophosphamide (50 mg daily) plus bevacizumab (10 mg/kg every 2 weeks). This combination has shown efficacy in advanced breast cancer with minimal toxicity.

Brand names

AvastinXeloda

Other names

metronomic capecitabine and cyclophosphamide combined with bevacizumabMCT-CX plus bevacizumab